Globalpharma Partners With ZIM Laboratories To Enhance Oral Drug Technology In The UAE

Globalpharma, a leading pharmaceutical manufacturer in the UAE and a subsidiary of Dubai Investments PJSC, has partnered with India's ZIM Laboratories. This collaboration aims to introduce EU-certified Oral Dispersible Film (ODF) technology to Globalpharma's expanding portfolio. The ODF technology has already achieved EU Good Manufacturing Practice (EU-GMP) certification, ensuring it meets top international quality and safety standards.

The agreement was announced at AIM Congress 2025, held from 7-9 April. It highlights the UAE's increasing role in global pharmaceutical innovation and its dedication to advanced healthcare solutions. The signing ceremony included notable figures such as Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade and Chairman of the Board of Emirates Drug Establishment (EDE).

Oral Dispersible Films offer a significant advancement in drug delivery. These thin strips dissolve quickly in the mouth without water, making them ideal for children, elderly patients, and those with swallowing difficulties. ZIM Labs' proprietary technology allows medications to be seamlessly incorporated into these films, improving patient compliance and treatment effectiveness.

Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma, signed the agreement alongside Zulfiquar Kamal, Promoter & Finance Director at ZIM Labs. Dr. Mariam Galadari, Board Member at Globalpharma, was also present during the signing.

Commenting on the partnership, Mohammed Saeed Al Raqbani stated that this collaboration with ZIM Labs is transformative for Globalpharma. "By bringing EU-certified ODF technology to the UAE," he said, "we are strengthening the region’s pharmaceutical capabilities and advancing patient-centric treatment options." This aligns with their vision to invest in innovations that elevate regional healthcare standards.

Dr. Basem Al-Barahmeh, General Manager of Globalpharma, emphasised the importance of this development: "By acquiring and localising ODF production within UAE facility, Globalpharma is not only introducing innovative treatments but also setting a benchmark for pharmaceutical manufacturing in the region."

ZIM Laboratories' Role

Zulfiquar Kamal from ZIM Labs highlighted the collaboration's significance: "This technology transfer with globalpharma is a significant milestone in our mission to expand access to patient-friendly drug delivery systems around the world." Their EU-GMP certified ODF technology combined with Globalpharma's regional reach will set new standards for pharmaceutical innovation in the GCC.

ZIM Laboratories Limited is a research-driven company that develops generic products in oral solid dosage forms across key therapeutic segments. With state-of-the-art R&D capabilities, they offer innovative drug delivery solutions using proprietary technology platforms aimed at enhancing patient convenience and adherence.

At AIM Congress 2025, Dr. Basem Al-Barahmeh delivered a keynote on the UAE’s emergence as a pharmaceutical manufacturing powerhouse. Additionally, Dr. Geeta Gujaran shared insights on industry trends during the "Leaders' Panel: Manufacturing 2030 – Key Trends Shaping the Industry," highlighting innovations shaping the sector.

This partnership marks an important step for both companies as they work towards advancing healthcare solutions globally while reinforcing their positions as leaders in pharmaceutical innovation.

With inputs from WAM